会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Methods and device for in vitro detection and characterization of psychoactives using analysis of repetitive electrical activity in a neuronal sample
    • 使用分析神经元样本中重复性电活动的心理活体的体外检测和表征的方法和装置
    • US06511817B1
    • 2003-01-28
    • US09602629
    • 2000-06-21
    • Gary LynchMakoto TaketaniKen ShimonoHirokazu Sugihara
    • Gary LynchMakoto TaketaniKen ShimonoHirokazu Sugihara
    • C12Q102
    • G01N33/48714G01N33/48707G01N33/5088G01N33/94
    • This relates to methods for the detection of psychoactive compounds in an in vitro neuronal tissue sample by detecting oscillations of extracellular voltage desirably before and after the introduction of a candidate sample onto an in vitro neuronal tissue sample and for devices useful in practicing the methods. Analysis of the extracellular voltage parameters leads to indication of the presence of psychoactive material in the candidate sample and information as to its pharmacological activity and/or composition. Further, it relates to a process of initiating and maintaining the presence of repetitive neuronal activity within the in vitro sample. Additionally, this includes a method for the stimulation of or initiation of repetitive neuronal activity, e.g., EEG, in an in vitro neuronal tissue sample by introducing a stimulating composition comprising compounds that facilitate or mimic the actions of acetylcholine, serotonin, or catecholamines, such as carbachol, or by subjecting the in vitro neuronal sample to electrical stimulation parameters.
    • 这涉及通过在候选样品引入体外神经元组织样品之前和之后检测细胞外电压的振荡以及用于实施该方法的装置来检测体外神经元组织样品中精神活性化合物的方法。 细胞外电压参数的分析导致候选样品中存在精神活性物质的迹象以及关于其药理活性和/或组成的信息。 此外,它涉及启动和维持体外样品中重复性神经元活性的存在的过程。 另外,这包括通过引入促进或模拟乙酰胆碱,5-羟色胺或儿茶酚胺的作用的刺激性组合物刺激或起始体外神经元组织样品中的重复性神经元活动(例如EEG)的方法, 作为卡巴胆碱,或通过使体外神经元样品经受电刺激参数。
    • 9. 发明授权
    • Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
    • 使用天冬氨酰蛋白酶抑制剂治疗神经变性疾病的方法
    • US07119105B2
    • 2006-10-10
    • US10774262
    • 2004-02-05
    • Jonathan A. EllmanGary LynchIrwin D. KuntzXiaoning BiChristina E. LeeA. Geoffrey SkillmanTasir Haque
    • Jonathan A. EllmanGary LynchIrwin D. KuntzXiaoning BiChristina E. LeeA. Geoffrey SkillmanTasir Haque
    • A99Z99/00
    • C07D209/48A61K31/36A61K31/4035A61K31/423A61K31/445A61K31/4465A61K31/4525A61K31/454C07D263/58C07D317/58C07D317/60C07D317/62C07D405/12C07D413/12C07D413/14
    • The present invention relates to () non-peptide aspartyl protease inhibitors; (ii) methods for modulating the processing of an amyloid precursor protein (APP); (iii) methods for modulating the processing of a tau protein (τ-protein); and (iv) methods for treating neurodegenerative diseases. For instance, in one embodiment, the present invention provides a method for modulating the processing of an amyloid precursor protein (APP), the method comprising contacting a composition containing the APP with an aspartyl protease inhibitor having the formula: wherein: R1, R2 and R3 are members independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl, substituted aryloxyalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heterocycles, substituted heterocycles, heterocyclicalkyl and substituted heterocyclicalkyl; and R5 and R6 are independently selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl and substituted aryloxyalkyl; or R5 and R6 and the carbons to which they are bound join to form an optionally substituted carbocyclic or heterocyclic fused ring system having a total of 9- or 10-ring atoms within the fused ring system.
    • 本发明涉及()非肽天冬氨酰蛋白酶抑制剂; (ii)调节淀粉样蛋白前体蛋白(APP)的加工的方法; (iii)调节tau蛋白(tau蛋白)的加工的方法; 和(iv)治疗神经变性疾病的方法。 例如,在一个实施方案中,本发明提供了调节淀粉样蛋白前体蛋白(APP)的加工的方法,所述方法包括将含有APP的组合物与具有下式的天冬氨酰蛋白酶抑制剂接触:其中: 1,R 2和R 3是独立地选自烷基,取代的烷基,芳基,取代的芳基,芳基烷基,取代的芳基烷基,芳氧基烷基 取代的芳氧基烷基,杂芳基,取代的杂芳基,杂芳基烷基,取代的杂芳基烷基,杂环,取代的杂环,杂环烷基和取代的杂环烷基; R 5和R 6独立地选自氢,卤素,烷基,取代的烷基,芳基,取代的芳基,芳基烷基,取代的芳基烷基,芳氧基烷基和取代的 芳氧基烷基; 或R 5和R 6和它们所连接的碳原子连接形成任选取代的碳环或杂环稠环体系,其具有总共9或10环 稠环体系内的原子。